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Abstract
           
Objectives
               MADIT   II   like   patients   have   not   been   compared   to   patients   without   an 
electrophysiological study, patients in whom ventricular tachycardia or fibrillation were induced 
in an electrophysiological study (EPS) and patients without an inducibility in EPS in one study.  
Background
            The multicenter automatic defibrillator implantation trial (MADIT) II showed a benefit 
of ICD implantation in patients with ischemic heart disease.                                                       
Methods 
            We performed a retrospective analysis in 93 patients with an ischemic heart disease and 
an ejection fraction ≤30% who had an ICD implanted with a follow-up at least an 18 months. 
Patients were divided into 3 groups according to the primary indication for ICD implantation: 
without EPS (group I), patients in whom ventricular tachycardia or fibrillation were inducible in 
EPS (group II) or patients without an inducibility in EPS (group III).                                 
Results 
            During the mean follow-up of 32.9 ± 16.1 months 289 appropriate ICD therapies and 10 
deaths occurred. The incidence of appropriate ICD therapies did not differ significantly between 
the groups (group I 40%, group II 54% and group III 48% of patients). We found in group II a 
higher risk of appropriate ICD therapies with occurrence of a specific constellation of EPS 
values. These patients showed a 15-fold risk (P = 0.005) of an appropriate ICD therapy. 
Furthermore a brain natriuretic peptide value of 265 pg/ml also predicted an appropriate ICD 
therapy with a 3.5-fold risk (P = 0.017).                                                                     
Conclusion
            In the present retrospective study the results of MADIT II were affirmed in the case of 
incidence of ventricular arrhythmias in patients with an EF < 30% and coronary heart disease. 
The prediction of an appropriate ICD therapy with EPS was only achieved in patients with 
inducibility in the EPS. 
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Introduction
            The multicenter automatic defibrillator implantation trial (MADIT) II showed a reduction 
of the risk of all-cause mortality by 31% over an average follow-up of 20 months in patients with 
an ejection fraction ≤30% and coronary heart disease1. The cost-effectiveness of ICDs after the 
implementation of the MADIT II results into the guidelines was discussed controversial2-6.  
            To the best of our knowledge there is no study which compared MADIT II like patients 
who did not undergo an electrophysical study (EPS), MADIT II like patients in whom 
ventricular tachycardia or fibrillation were inducible in EPS and MADIT II like patients without 
an inducibility in EPS in one study. Daubert et al. compared the MADIT II patients with and 
without inducibility in EPS but they did not compare those patients who underwent an EPS to 
patients who did not undergo an EPS7. It is unclear whether MADIT II patients provided from an 
EPS   or   a  subgroup   of   patients   could   be   identified   with   higher   risk   for   ICD   therapy.
            Therefore we performed a retrospective analysis of MADIT II like patients with regard to 
an appropriate ICD therapy. In addition we performed an analysis of demographic data, NYHA 
classification, brain natriuretic peptide (BNP) and echocardiographic measurements for the 
prediction   of   an   appropriate   ICD   therapy.                                                        
Methods
            We enrolled 93 patients with coronary heart disease and myocardial infarction who have 
had a follow-up at least of 18 months between January 2003 and December 2006 in a 
retrospective study. The myocardial infarction had to be at least one month prior to ICD 
implantation and the EF had to be ≤ 30%. The ICD was implanted because of inducibility of 
ventricular fibrillation (VF) (11 patients) or monomorphic ventricular tachycardia (VT) (18 
patients) in EPS (group II), in 27 patients without inducibility in EPS (group III) or a primary 
indication (37 patients = group I) due to the MADIT II criteria1 without performing an EPS. The 
EPS was performed in patients of group II and III because of unclear results (artefacts, triplet, 
bigeminy, non-sustained VT) in 24h-Holter ECG. Defibrillator systems were manufactured by 
Biotronik GmbH & Co (Berlin, Germany), Guidant Corp. (St. Paul, MN), Medtronic Inc. 
(Minneapolis,   MN)   and   St.   Jude   Medical   CRMD   (Sylmar,   CA)   (alphabetical   order).
            Antitachycardia therapy was standardized providing for VT cycle lengths raging from 
450 to 300 ms. The cut-off cycle length of ICD with immediate shock delivery (VF zone) was < 
300 ms in all patients, Antibradycardia pacing was programmed with basic drive of 40 bpm/min 
for single chamber ICD, and 50 bpm/min for dual chamber or CRT ICD´s. The study protocol 
was approved by the institutional review board.                                                                   
Study   end   points                                                                      
            The primary end point of the study was the occurrence of an appropriate ICD therapy. 
The secondary end point was death.                                                             
Electrophysiological  study and definition of inducibility                                         
        
            In all patients of group II and III an EPS was performed with up to 3 extrastimuli from 
two different right ventricular sites during sinus rhythm or atrial fibrillation and basic drive 
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pacing (8 beats) at cycle lengths of 500, 430, 370 and 330 ms with a S2 and S3 stimulation as 
well as at cycle lengths of 500 ms with a S4 stimulation. If it was required S4 stimulation was 
performed at cycle lengths of 500 ms. The ventricular extrastimulus was twice the diastolic 
threshold and 2 ms duration. Extrastimuli were decrementally down to the coupling interval no 
shorter than 200 ms or to the ventricular refractory period. The endpoint of the EPS was the 
completion   of   the  stimulation   protocol   or  induction   of   VF,  sustained   monomorphic   or 
polymorphic VT. Rapid burst pacing was not used for induction of VF.                      
            A sustained ventricular tachycardia was defined as lasting 30 sec or requiring termination 
sooner because of a hemodynamic compromise. A monomorphic VT was defined as VT with a 
uniform beat-to-beat surface QRS morphology. A polymorphic VT had a variable surface QRS 
morphology, and VF was defined as a rapid, disorganized rhythm without  identifiable QRS 
complexes.
 
            We analysed retrospectively the data of EPS in order to reach a subdivision of patients 
with induction of VF, sustained monomorphic or polymorphic VT. First we performed a ROC 
analysis for the particular S2, S3 and S4 refractory periods of patients without induction of 
ventricular arrhythmias and the induction interval of patients with inducibility of ventricular 
arrhythmias. Second we analysed the differences of the particular S2, S3 and S4 refractory 
periods (ΔP) of patients without induction of ventricular arrhythmias and the induction interval 
of patients with inducibility of ventricular arrhythmias. Therefore we calculated the differences 
(ΔP) between S2 vs. S3, S2 vs. S4 and S3 vs. S4.                                                         
            We defined an abnormal EPS as following: First extrastimulus below 400 ms and ΔP of 
≤ 20 ms between second (S2) and third (S3) extrastimulus or first extrastimulus above 400 ms 
and ΔP > 20 ms between second and third extrastimulus or whether a 500 S4 was performed the 
difference between third and fourth extrastimulus of ≤ 20 ms in patients with inducibility of 
ventricular arrhythmias. A definition of an abnormal EPS in patients without inducibility 
achieved no significant difference in patients with or without ICD therapy with these methods.   
Analysis   of   ICD   therapy                                                                  
            We used the interrogable data of the ICD to analyse appropriate ICD therapy every three 
months. ICD therapy  for VF or VT was defined as appropriate therapy, and ICD therapy  for 
atrial fibrillation, supraventricular tachycardia, sinus tachycardia or abnormal sensing was 
defined   as   inappropriate   therapy.                                                                            
            A VT was characterized with uniform and regular complexes between 170 and 250 beats/
min. VF was defined as an irregular rhythm with > 200 beats/min and indistinct electrogram 
complexes. A polymorphic VT was classified as VT when < 200 beats/min and as VF when the 
rate was > 200 beats/min1. VT was differentiated from supraventricular tachycardias using 
standard criteria, including a change in electrogram morphology, sudden onset and atrial-
ventricular relationship if atrial electrograms were available.                                               
Brain   natriuretic   peptide                                                                        
            Patients have had their venous blood samples drawn from a forearm vein for BNP 
concentration. BNP measurement (Triage Meter Plus®, Biosite GmbH, Willich, Germany) was 
performed randomly during working hours in all patients 1-3 days before ICD implantation. The 
detection limit was 5 pg/ml and upper measurement limit was 5000 pg/ml. Samples were 
analysed by personnel blinded to the patients clinical data. We performed a retrospective 
analysis of our data to define a margin.                                                                               
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Echocardiography
            The physicians were blinded to the clinical data of the patients. Biplanar left ventricular 
end-diastolic and end-systolic cavity volumes were calculated using Simpson's rule8 from paired 
apical four-chamber and apical long-axis echocardiographic images of a minimum of five 
cardiac cycles; mean values of each variable were estimated. Biplanar ejection fractions were 
calculated as end-diastolic volume – end-systolic volume / end-diastolic volume x 100%9. Left 
ventricular systolic and end-diastolic diameter of all patients was measured by M-mode and two-
dimensional echocardiography using the Phillips ultrasonic device (3.5 MHz; model Sonos 5500, 
Philips Medical System, Andover, Massachusetts, USA).                                                             
Statistics
            All data are presented as mean values ± standard deviation for continuous variables and 
as percentages for categorical variables. Discrepancies in proportions were evaluated for 
statistical significance using the chi-square or Fisher's exact test. Student´s t-test was used 
comparing continuous variables except of BNP value, as its distribution was skewed. Here, the 
Mann-Whitney U test was employed. All statistical tests were two-tailed. The diagnostic cut off 
value for parameters (BNP, left ventricular end-systolic diameter, left end-diastolic diameter, left 
ventricular end-diastolic volume, left ventricular end-systolic volume, cycle length of induced 
VT, cycle length of induced VF) was calculated by means of receiver-operating characteristics 
(ROC) curves. The values of EPS were analysed with ROC curve, chi-square or Fisher´s exact 
test for prediction of appropriate ICD therapy. The Kaplan-Meier analysis with a log-rank test 
was used to compare the probability of ICD therapy. A multivariate Cox regression analysis was 
performed on variables regarded as significant predictors (p < 0.1) with a univariate analysis for 
appropriate an ICD therapy. A P value of ≤ 0.05 was considered as significant. The statistical 
package used  was  SPSS 12.0  for Windows.                                                           
Results
            During a mean follow-up of 32.9 ± 16.1 months an appropriate ICD therapy occurred in 
43 (46%) patients and an inappropriate ICD therapy occurred in 9 (10 %) patients. The clinical 
characteristics of the three groups were similar (Table 1). Patients of group II had a higher 
incidence of a posterior wall infarction and a lower incidence of an anterior wall infarction than 
those of the other groups (Table 1). The echocardiographic parameters were also similar with 
the exception of a larger left ventricular end-diastolic and end-systolic diameter of group I than 
of group II (Table 2).
Incidence   of   ICD   therapy                                                                  
            The incidence of an appropriate (group I 40%, group II 54% and group III 48% of 
patients) and inappropriate (group I 10 %, group II 8%, group III 11% of patients) ICD therapy 
was similar between the three groups. The long-rank test was also similar between the three 
groups (Figure 1). The number of treated VT´s (group I 25%, group II 30% and group III 28% 
of patients) or VF (group I 15%, group II 24% and group III 20% of patients) did also not differ.
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Table 1: Patients characteristics in comparison to electrophysical study
Table 2: Comparison of echocardiographic parameters to electrophysical study
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Figure 1: Kaplan Meier Analysis for appropriate ICD therapy. (group I = light-grey line, group II = black line, 
group III = dark-grey line) long-rank P = 0.24 for group I vs. II, long-rank P = 0.17 for group I vs. III, 
long-rank P = 0.33 for group II vs. III.
Comparison of patients with and without ICD therapy                                                       
            Patients with an appropriate ICD therapy had a significantly higher BNP value, a higher 
incidence of a sotalol, digitalis and ACE inhibitor/angiotensin receptor antagonists therapy than 
patients without an appropriate ICD therapy (Table 3). The echocardiographic parameters 
showed a significant left ventricle enlargement in patients with an appropriate ICD therapy and a 
similar left ventricular ejection fraction between patients with and without an ICD therapy 
(Table 4). 
            The ROC curve analysis revealed a threshold for left ventricular end-diastolic volume 
(172 ml, AUC 0.637, P = 0.023) and BNP (265 pg/ml, AUC 0.647, P = 0.015) for a significant 
prediction of appropriate ICD therapy (Figures 2, 3). Left ventricular end-systolic diameter, left 
end-diastolic diameter, left ventricular end-systolic volume, cycle length of induced VT and 
cycle length of induced VF did not achieve a significant value. The long-rank test showed a 
significant difference for BNP ≥ 265 pg/ml (P = 0.016) (Figure 4). The incidence of appropriate 
ICD therapies was significantly higher in patients with a BNP ≥ 265 pg/ml compared to in 
patients with a BNP < 265 pg/ml [27 vs. 16 patients (60 vs. 33%), P = 0.013]. BNP (265 pg/ml) 
predicted an appropriate ICD therapy with a 3.5-fold risk (P = 0.017). 
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Table 3: Patients characteristics in comparison to appropriate ICD therapy
Table 4: Comparison of echocardiographic parameters to appropriate ICD therapy
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Figure 2: Receiver-operating characteristics curves of BNP
(area under the curve 0.647, P = 0.015)
Figure 3: Receiver-operating characteristics curves of left ventricular end-diastolic volume 
(area under the curve 0.637, P = 0.023)
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Figure 4: Kaplan Meier analysis for BNP
(BNP ≥ 265 pg/ml = black line, BNP < 265 pg/ml = grey line)
            The Kaplan-Meier analysis did not achieve a significant difference for left ventricular 
end-diastolic volume ≥ 172 ml (P = 0.66) (Figure 5).
Figure 5: Kaplan Meier analysis for left ventricular end-diastolic volume (LVEDV ≥ 172 ml = 
black line, LVEDV < 172 ml = grey line)
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            The prediction of an appropriate ICD therapy was achieved by an abnormal EPS. Patients 
who fulfilled the definition had a significantly higher incidence of an appropriate ICD therapy 
than patients who did not fulfil the definition (85 vs. 27% of patients, P = 0.005). The results of  
group II with abnormal EPS results could not be assigned to group III patients. 13 patients 
fulfilled the definition of abnormal EPS but only 5 received an ICD therapy.  An abnormal EPS 
did not achieve a significant difference between patients with and without ICD therapy (38 vs. 
50% of patients). The Kaplan-Meier analysis showed a significant difference between patients 
with normal and abnormal EPS (Figure 6). EPS values of non-inducible patients could not 
predict an appropriate ICD therapy.
Figure 6: Kaplan Meier analysis for abnormal EPS 
(abnormal EPS = black line, normal EPS = grey line)
Prediction   of   death
               There was no significant difference between dead and alive patients in clinical 
characteristics with the exception of a higher BNP level in dead than alive patients (421.5 ± 
433.4 vs. 307.5 ± 188.3 pg/ml, P = 0.011). A prediction of death could not be achieved by any 
parameter.
Discussion
            In the present retrospective study we showed that MADIT II like patients did not differ in 
occurrence of an appropriate ICD therapy in relation to a performance of an EPS. Only patients 
with an induction of ventricular arrhythmias benefited from an EPS for a prediction of an 
appropriate ICD therapy. BNP was significantly higher in patients with an appropriate ICD and 
was able to predict an appropriate ICD therapy. Patients with an appropriate ICD therapy 
showed a left ventricular enlargement without the possibility to predict an appropriate ICD 
therapy.
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Electrophysiological study and appropriate ICD therapy                                             
            An EPS was not suitable to predict an appropriate ICD therapy in patients with who 
underwent an EPS. A prediction of an appropriate ICD therapy was only achieved in a subgroup 
of patients with inducibility of ventricular arrhythmias in EPS. Patients without an induction of a 
ventricular arrhythmia also had a high incidence of ventricular arrhythmias in our study that was 
also found in similar studies7,  10-18. A subgroup analysis of MADIT II like patients who 
underwent an EPS showed that inducible and non-inducible patients had similar ICD therapies 
(long-rank P = 0.280)7. Furthermore inducible patients had a greater likelihood of experiencing 
ICD therapy for VT than non-inducible patients and ICD therapy for VF was more common in 
non-inducible patients than in inducible patients7. Similar results were also observed in 
Antiarrhythmics versus Implantable Defibrillators (AVID) trial11. In the AVID trial patients with 
induction of a slow VT (< 200 bpm) showed a significantly higher incidence of appropriate ICD 
therapy (P = 0.004)11. The results of the Cardiac Arrest Study Hamburg (CASH) indicated that 
patients with an EF < 35% did not differ in all-cause death or sudden cardiac death in 
comparison to patients with inducible or non-inducible in EPS17. A prediction of all-cause death 
and sudden cardiac death by EPS was achieved in patients with an EF > 35%18. Ruppel et al. 
observed a weak prediction of EPS for recurrence of VF and VT in patients who survived an 
episode   of   VF10.                                                                      
            In contrast to the results of the previous studies other authors found a prediction of 
appropriate ICD therapy by induction of VT or VF with EPS10,12-16,18 but without a definition of 
an abnormal EPS constellation.  The most meaningful example for the prediction of an 
appropriate ICD therapy by EPS was the Multicenter Unsustained Tachycardia Trail (MUSTT), 
which showed a lower risk of appropriate ICD therapy in patients without induction in EPS13. 
But it was remarkable that non-inducible patients had a high incidence of appropriate ICD 
therapy in studies in which EPS could well predict an appropriate ICD therapy10,12-14,16-18.  
            Only patients who fulfilled the definition of an abnormal EPS reached a significantly 
higher incidence of appropriate ICD therapy than patients who did not fulfil the definition in our 
study. To the best of our knowledge this was the first study with a prediction of an appropriate 
ICD therapy by values of EPS. However, an EPS could predict an appropriate ICD therapy and 
particularly in regard to an abnormal EPS. But non-inducible patients also had a high risk for an 
appropriate   ICD   therapy.                                                                  
Brain   natriuretic   peptide                                                                        
            BNP was significantly higher in patients with appropriate ICD therapy and reached a 
prediction of a BNP appropriate ICD therapy in MADIT II like patients. A prediction of death 
could not be achieved by our study. However, BNP was an excellent predictor for sudden death 
and heart failure19-23. In addition, Verma et al. also observed a higher value of BNP in patients 
with an appropriate ICD therapy (573 vs. 243 pg/ml, P = 0.0003) and predicted an appropriate 
ICD therapy by a BNP value of 263 pg/ml (long rank P = 0.006) in their study24. Manios et al. 
found a higher NT-proBNP value in patients with an EF < 35% (997.27 vs. 654.87 pmol/l, P = 
0.001) and predicted an appropriate ICD therapy with a NT-proBNP value of 880 pmol/l with a 
sensitivity of 73%, a specificity of 88%, a positive predictive value of 80% and a negative 
predictive value of 88%25. In consensus of these studies BNP was an excellent predictor for 
sudden death, heart failure and appropriate ICD therapies.                                             
Limitations
            The number of patients is lower in comparison to the larger trials like MADIT II, AVID 
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or CASH in our study. The evaluation of the EPS parameters and BNP value were performed 
retrospectively. Our preliminary observations are important aspects for a prospective trial of the 
predictive power of abnormal EPS and BNP value. The three groups were comparable in their 
clinical characteristics except for the location of myocardial infarction. To the best of our 
knowledge the location of myocardial infarction did not influence the outcome of patients with 
ICD's.
            In conclusion, our study results suggest that abnormal EPS and BNP value predicted an 
appropriate ICD therapy in MADIT II like patients. The abnormal EPS could only be applied in 
patients with an induction of ventricular arrhythmia in EPS. Many patients who received an 
appropriate ICD therapy were non-inducible in EPS or got an ICD implanted without an EPS 
according to the MADIT II criteria. Thus MADIT II patients were high-risk patients for an 
appropriate ICD therapy and should be implanted an ICD independent from an EPS.
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